Minimising the environmental impact of inhaled therapies
- 27 May 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (5), 2000721
- https://doi.org/10.1183/13993003.00721-2020
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Emergency MDI and spacer packs for asthma and COPDThe Lancet. Respiratory Medicine, 2019
- The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database studyInternational Journal of Chronic Obstructive Pulmonary Disease, 2017
- Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?Drug Delivery, 2017
- The Finnish experience to save asthma costs by improving care in 1987-2013Journal of Allergy and Clinical Immunology, 2016
- Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®Patient Preference and Adherence, 2016
- Inhaler Use in Hospitalized Patients with Chronic Obstructive Pulmonary Disease or Asthma: Assessment of Wasted DosesHospital Pharmacy, 2015
- The Importance of Continuity in Inhaler Device Choice for Asthma and Chronic Obstructive Pulmonary DiseaseRespiration, 2014
- Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long‐acting β 2 ‐agonists in obstructive lung diseases: a population‐based, observational studyInternational Journal of Clinical Practice, 2014
- Correct inhalation technique is critical in achieving good asthma controlPrimary Care Respiratory Journal, 2013
- Device type and real-world effectiveness of asthma combination therapy: An observational studyRespiratory Medicine, 2011